Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis Patients

NCT ID: NCT05956899

Last Updated: 2024-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2024-05-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to compare the effectiveness of two antiemetic drugs, palonosetron and ondansetron, when given alongside dexamethasone as a preventive measure against early and delayed postoperative nausea and vomiting (PONV) in adult and adolescent patients with idiopathic scoliosis undergoing posterior spinal fusion surgery under total intravenous anesthesia (TIVA).

The main questions the study aims to answer are:

* How effective is palonosetron compared to ondansetron, both combined with dexamethasone, in preventing PONV after scoliosis surgery?
* Are there any differences in the need for rescue antiemetics, occurrence of adverse effects related to the study drugs, and patient satisfaction between the two treatment groups?

Participants in the study will be randomly assigned to receive either palonosetron or ondansetron in addition to dexamethasone as part of their anesthesia and antiemetic regimen. The incidence and/ or severity of nausea, vomiting and retching will be assessed at 1 hour, 4 hours, 12 hours, 24 hours and 48 hours after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND/ JUSTIFICATION Postoperative nausea and vomiting (PONV) is a common complication following surgery and can cause significant morbidity. It occurs in 20-30% of the general population and up to 75-80% in high-risk groups. Children have a higher incidence of PONV compared to adults. PONV can occur at various timeframes after surgery and has clinical and financial consequences, including wound complications, dehydration, and prolonged hospitalization. Prevention and treatment of PONV are crucial for comprehensive perioperative care.

Posterior spinal fusion surgery for idiopathic scoliosis is a complex and painful procedure, increasing the risk of PONV. Various strategies can be employed to mitigate these risks, such as adequate hydration, the use of intravenous antiemetics, avoiding volatile anesthetics, and adopting a multimodal analgesic approach. Dexamethasone and anti-serotonergic drugs like ondansetron are commonly used antiemetics due to their efficacy and safety profiles. Dexamethasone is particularly favored for its long duration of action and pain-reducing effects.

Palonosetron, a second-generation anti-serotonergic drug, has a unique pharmacokinetic profile with a prolonged duration of action. It may be more beneficial for patients on prolonged opioid-based analgesic regimens. However, its higher cost and inconsistent study findings limit its widespread use, especially in scoliosis patients undergoing spinal fusion surgery.

Total intravenous anesthesia (TIVA) is recommended for high-risk PONV patients, as it reduces the emetogenic effect of volatile anesthetics. Propofol, used in TIVA, is itself an effective antiemetic. TIVA with propofol has been shown to be as effective as giving a single antiemetic and can further reduce the risk of PONV when combined with other prophylactic antiemetics.

The standard practice for managing PONV involves the administration of two antiemetics and considering TIVA for high-risk patients. This study aims to compare the effectiveness of palonosetron and ondansetron when administered alongside dexamethasone in scoliosis patients undergoing spinal fusion under TIVA. The study will also evaluate the number of rescue antiemetics needed, assess adverse effects, and measure patient satisfaction.

The study will be randomized and double-blinded, to be conducted in Universiti Malaya Medical Centre (UMMC). The sample size is calculated to be 92 participants, after taking into account a 20% dropout rate. Adult and adolescent idiopathic scoliosis patients undergoing posterior spinal fusion surgery will be eligible for the study. Written informed consent will be obtained from participants or their guardians, and assent will be obtained from adolescent participants. Patients will be randomized to receive either palonosetron or ondansetron along with dexamethasone.

The study will follow standard anesthetic techniques, including TIVA with remifentanil and propofol. Intravenous injections of the study drugs or placebo will be given during surgery, and dexamethasone will be administered as a baseline antiemetic. Morphine will be administered before the end of surgery for pain management.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Scoliosis Postoperative Nausea and Vomiting

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Antiemetics Dexamethasone Ondansetron Palonosetron Scoliosis PONV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

After taking informed consent and recruitment of eligible participants, they will be randomized using a sequentially numbered, opaque sealed envelope (SNOSE) method. 74 radio-opaque envelopes will be prepared according to two groups: 37 participants for each Group A, Palonosetron and Group B, Ondansetron. Group A will receive IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia; while Group B will receive IV ondansetron 0.15mg/kg at the start of wound closure.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Group A will receive a stat dose of IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia.

Group Type EXPERIMENTAL

Palonosetron

Intervention Type DRUG

IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia

Group B

Group B will receive a stat dose of IV ondansetron 0.15mg/kg at the start of wound closure.

Group Type ACTIVE_COMPARATOR

Ondansetron

Intervention Type DRUG

IV ondansetron 0.15mg/kg at the start of wound closure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Palonosetron

IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia

Intervention Type DRUG

Ondansetron

IV ondansetron 0.15mg/kg at the start of wound closure

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age of 10 years and above
* American Society of Anaesthesiologists (ASA) I-II Physical Status

Exclusion Criteria

* History of allergy to serotonin receptor antagonists or dexamethasone
* Obesity with a body mass index (BMI) of 34 and above
* Body weight of less than 30kg
* Active smoker
* History of gastroesophageal reflux disease/ other gastrointestinal diseases associated with vomiting
* History of motion sickness
* History of nausea or vomiting within 24 hours before the surgery
* Administration of antiemetics/ steroids/ psychoactive medications within 24 hours before the surgery
* Require mechanical ventilation postoperatively
* History of cardiac arrhythmias
* Prolonged QT (QTc is prolonged if \> 440ms in men or \> 460ms in women
Minimum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Malaya

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Siti Nadzrah Yunus

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Siti Nadzrah Binti Yunus, MAnaes, MBBS

Role: PRINCIPAL_INVESTIGATOR

Universiti Malaya

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Malaya

Pantai Valley, Kuala Lumpur, Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

References

Explore related publications, articles, or registry entries linked to this study.

Kumar A, Solanki SL, Gangakhedkar GR, Shylasree TS, Sharma KS. Comparison of palonosetron and dexamethasone with ondansetron and dexamethasone for postoperative nausea and vomiting in postchemotherapy ovarian cancer surgeries requiring opioid-based patient-controlled analgesia: A randomised, double-blind, active controlled study. Indian J Anaesth. 2018 Oct;62(10):773-779. doi: 10.4103/ija.IJA_437_18.

Reference Type BACKGROUND
PMID: 30443060 (View on PubMed)

Kotiniemi LH, Ryhanen PT, Valanne J, Jokela R, Mustonen A, Poukkula E. Postoperative symptoms at home following day-case surgery in children: a multicentre survey of 551 children. Anaesthesia. 1997 Oct;52(10):963-9. doi: 10.1111/j.1365-2044.1997.203-az0338.x.

Reference Type BACKGROUND
PMID: 9370838 (View on PubMed)

Villeret I, Laffon M, Duchalais A, Blond MH, Lecuyer AI, Mercier C. Incidence of postoperative nausea and vomiting in paediatric ambulatory surgery. Paediatr Anaesth. 2002 Oct;12(8):712-7. doi: 10.1046/j.1460-9592.2002.00952.x.

Reference Type BACKGROUND
PMID: 12472709 (View on PubMed)

Patel RI, Hannallah RS. Anesthetic complications following pediatric ambulatory surgery: a 3-yr study. Anesthesiology. 1988 Dec;69(6):1009-12. doi: 10.1097/00000542-198812000-00044. No abstract available.

Reference Type BACKGROUND
PMID: 3195743 (View on PubMed)

Rowley MP, Brown TC. Postoperative vomiting in children. Anaesth Intensive Care. 1982 Nov;10(4):309-13. doi: 10.1177/0310057X8201000402.

Reference Type BACKGROUND
PMID: 7158749 (View on PubMed)

Awad IT, Moore M, Rushe C, Elburki A, O'Brien K, Warde D. Unplanned hospital admission in children undergoing day-case surgery. Eur J Anaesthesiol. 2004 May;21(5):379-83. doi: 10.1017/s0265021504005058.

Reference Type BACKGROUND
PMID: 15141796 (View on PubMed)

Kovac AL. Update on the management of postoperative nausea and vomiting. Drugs. 2013 Sep;73(14):1525-47. doi: 10.1007/s40265-013-0110-7.

Reference Type BACKGROUND
PMID: 24057415 (View on PubMed)

Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. Br J Anaesth. 2002 Sep;89(3):409-23.

Reference Type BACKGROUND
PMID: 12402719 (View on PubMed)

Golembiewski J, Chernin E, Chopra T. Prevention and treatment of postoperative nausea and vomiting. Am J Health Syst Pharm. 2005 Jun 15;62(12):1247-60; quiz 1261-2. doi: 10.1093/ajhp/62.12.1247.

Reference Type BACKGROUND
PMID: 15947124 (View on PubMed)

Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000 Feb;59(2):213-43. doi: 10.2165/00003495-200059020-00005.

Reference Type BACKGROUND
PMID: 10730546 (View on PubMed)

Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700. doi: 10.1097/00000542-199909000-00022.

Reference Type BACKGROUND
PMID: 10485781 (View on PubMed)

Apfel CC, Kranke P, Eberhart LH, Roos A, Roewer N. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth. 2002 Feb;88(2):234-40. doi: 10.1093/bja/88.2.234.

Reference Type BACKGROUND
PMID: 11883387 (View on PubMed)

Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, Jin Z, Kovac AL, Meyer TA, Urman RD, Apfel CC, Ayad S, Beagley L, Candiotti K, Englesakis M, Hedrick TL, Kranke P, Lee S, Lipman D, Minkowitz HS, Morton J, Philip BK. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2020 Aug;131(2):411-448. doi: 10.1213/ANE.0000000000004833.

Reference Type BACKGROUND
PMID: 32467512 (View on PubMed)

Eberhart LHJ, Geldner G, Kranke P, Morin AM, Schauffelen A, Treiber H, Wulf H. The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. Anesth Analg. 2004 Dec;99(6):1630-1637. doi: 10.1213/01.ANE.0000135639.57715.6C.

Reference Type BACKGROUND
PMID: 15562045 (View on PubMed)

Palmer GM, Pirakalathanan P, Skinner AV. A multi-centre multi-national survey of anaesthetists regarding the range of anaesthetic and surgical practices for paediatric scoliosis surgery. Anaesth Intensive Care. 2010 Nov;38(6):1077-84. doi: 10.1177/0310057X1003800619.

Reference Type BACKGROUND
PMID: 21226441 (View on PubMed)

Ho CM, Wu HL, Ho ST, Wang JJ. Dexamethasone prevents postoperative nausea and vomiting: benefit versus risk. Acta Anaesthesiol Taiwan. 2011 Sep;49(3):100-4. doi: 10.1016/j.aat.2011.06.002.

Reference Type BACKGROUND
PMID: 21982171 (View on PubMed)

Wakamiya R, Seki H, Ideno S, Ihara N, Minoshima R, Watanabe K, Sato Y, Morisaki H. Effects of prophylactic dexamethasone on postoperative nausea and vomiting in scoliosis correction surgery: a double-blind, randomized, placebo-controlled clinical trial. Sci Rep. 2019 Feb 14;9(1):2119. doi: 10.1038/s41598-019-38764-8.

Reference Type BACKGROUND
PMID: 30765809 (View on PubMed)

Kloth DD. New pharmacologic findings for the treatment of PONV and PDNV. Am J Health Syst Pharm. 2009 Jan 1;66(1 Suppl 1):S11-8. doi: 10.2146/ashp080462.

Reference Type BACKGROUND
PMID: 19106333 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20221016-11624

Identifier Type: -

Identifier Source: org_study_id